Programmed Cell Death: A Key Mechanism of Traditional Chinese Medicine in the Treatment of Membranous Nephropathy Authors: Xixi Han, Jingwen Kong, Baike Liu, Chao Wei Published: 2026 ABSTRACT BackgroundMembranous nephropathy (MN) is the leading cause of adult nephrotic syndrome with rising global incidence. A substantial proportion of patients progress to end-stage renal disease. Multiple programmed cell death (PCD) pathways—including apoptosis, pyroptosis, ferroptosis, and autophagy—are activated by complement-dependent and -independent pathogenic factors, collectively driving podocyte injury and MN progression. Current immunosuppressive therapies are limited by adverse reactions and variable responses. Traditional Chinese medicine (TCM), characterized by multi-component, multi-target, and multi-pathway regulation, shows therapeutic advantages in MN.PurposeTo systematically review the regulatory mechanisms of PCD in MN, summarize the molecular basis of TCM interventions targeting PCD, and identify current research limitations and future directions.MethodsThis narrative review systematically elaborates the regulatory association between PCD and podocyte injury in MN. Literatures were systematically retrieved from PubMed, Embase and China National Knowledge Infrastructure (CNKI) from the establishment of each database to May 2026, and 41 preclinical studies exploring TCM modulation of PCD in MN were included after strict screening.ResultsComplement-dependent and complement-independent pathways in MN can synergistically initiate podocyte apoptosis, pyroptosis, ferroptosis, and autophagy dysfunction. TCM can regulate PCD through core signaling pathways such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), nuclear factor erythroid 2-related factor 2/heme oxygenase 1 (Nrf2/HO-1), mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase/forkhead box O1 (JNK/FoxO1), and PTEN-induced kinase 1/Parkin (PINK1/Parkin), while simultaneously intervening in non-PCD pathological processes including inflammation, oxidative stress, and renal fibrosis. Clinical evidence further indicates that TCM or combined with conventional therapy can elevate MN remission rates and decrease adverse reactions.ConclusionPCD represents a core mechanism mediating podocyte injury and MN progression. TCM effectively modulates PCD imbalance through multi-target regulation, demonstrating prominent clinical efficacy and safety. These findings provide a theoretical basis and translational direction for developing high-efficacy, low-toxicity therapeutic strategies for MN. Introduction Membranous nephropathy (MN), a refractory glomerular disorder and the leading cause of adult nephrotic syndrome, is characterized predominantly by massive proteinuria resulting from podocyte injury and impairment of the renal filtration barrier. Its pathological hallmark is subepithelial deposition of immune complexes along the glomerular basement membrane (GBM), accompanied by GBM thickening.1,2 MN is categorized into primary membranous nephropathy (PMN) and secondary membranous nephropathy (SMN). PMN accounts for approximately 80% of all MN cases, which is primarily triggered by autoantibodies targeting podocyte antigens, among which phospholipase A2 receptor (PLA2R) and thrombospondin type‑1 domain‑containing 7A (THSD7A) represent the most common pathogenic antigens. By contrast, SMN develops secondary to systemic disorders including systemic lupus erythematosus, hepatitis B virus infection, and malignant malignancies. Epidemiological investigations have demonstrated that the global annual incidence of MN ranges from 8 to 17 cases per million population.3 Over recent years, the global incidence of MN has been rising continuously. Large-scale renal biopsy-based cohort studies have demonstrated a striking increase in the proportion of MN among primary glomerular diseases, making it the second most common cause following IgA nephropathy.4,5 MN may occur across all age groups, with the highest prevalence observed in males aged 40–60 years. Sustained edema, persistent fatigue, elevated infection risk, and recurrent hospitalizations collectively impose a substantial physical and psychological burden on affected patients. Notably, severe cases may develop life-threatening complications such as thromboembolism and acute kidney injury, and approximately one-third of patients eventually progress to end-stage renal disease (ESRD).6–8 Programmed cell death (PCD) constitutes a genetically regulated, active, and orderly form of cellular demise encompassing necroptosis, apoptosis, pyroptosis, ferroptosis, autophagy, and other discrete modalities. As a fundamental safeguard of cellular homeostasis, PCD is tightly controlled under physiological conditions. In MN, antigen-antibody immune complexes initiate complement activation, ultimately leading to the extracellular assembly of the membrane attack complex (MAC, C5b-9).3,9 Sublytic C5b-9 inserts into podocyte membranes, triggers podocyte cytoskeletal disruption and a cascade of intracellular stress responses, and further modulates PCD to drive MN pathogenesis, ultimately exacerbating podocyte injury.10–12 Specifically, apoptosis generally marks irreversible podocyte injury and progressive deterioration of MN; pyroptosis triggers podocyte lysis and the release of pro-inflammatory cytokines, thereby exacerbating inflammatory storms and renal fibrosis; ferroptosis is distinguished by iron-dependent lipid peroxidation, which disrupts podocyte membrane integrity and induces mitochondrial shrinkage; and both insufficient and excessive autophagy directly contribute to podocyte dysfunction and injury.12–16 More importantly, PCD does not operate in isolation. Distinct PCD modalities share common upstream signaling triggers and core regulatory nodes, and may be dysregulated simultaneously under pathological conditions.17–19 Therefore, the simultaneous dysregulation of multiple PCD processes may serve as a central driver of podocyte injury, representing a pivotal entry point for dissecting the molecular pathogenesis of MN and developing innovative therapeutic interventions. Therapeutic strategies for MN have gradually evolved from cyclophosphamide and calcineurin inhibitors to the application of anti-CD20 monoclonal antibodies (eg, rituximab), representing a pivotal paradigm shift from broad-spectrum immunosuppression toward precision medicine. Three landmark randomized controlled trials, including MENTOR, STARMEN, and RI-CYCLO, have compared the efficacy of rituximab, calcineurin inhibitors, and cyclophosphamide in MN treatment, and collectively demonstrated the superior remission efficacy of rituximab.20 The 2021 KDIGO glomerulonephritis guidelines have recommended rituximab as a first-line therapy for high-risk MN patients. Nevertheless, therapeutic responses vary substantially among individuals. Moreover, evidence supporting the efficacy of rituximab in delaying ESRD progression in high-risk patients with rapidly deteriorating renal function remains insufficient. In addition, these regimens are associated with severe adverse complications, including diabetes mellitus, osteoporosis, increased infection susceptibility, and systemic organ toxicity.21–23 Consequently, there exists an urgent clinical demand for effective, low-toxicity alternative therapeutic agents. Traditional Chinese medicine(TCM) possesses a longstanding history in the clinical management of kidney diseases. Its holistic treatment principles based on syndrome differentiation, compound formula compatibility, and strengthening healthy qi to eliminate pathogenic factors well align with the complex and multifactorial pathophysiology of MN.24 Accumulating evidence indicates that TCM yields substantial benefits by elevating clinical remission rates, alleviating characteristic symptoms, and reducing treatment-related adverse effects.25 Mechanistically, TCM acts via a multi‑component, multi‑target, and multi‑pathway regulatory paradigm, rendering it uniquely suited to simultaneously modulate multiple PCD processes in MN.26,27 Over recent years, mounting preclinical and clinical investigations have validated that TCM effectively attenuate podocyte injury by targeting PCD, thereby offering novel insights and translational opportunities for the clinical management of MN. However, current studies on the regulatory effects of PCD in MN are relatively fragmented. Available reviews only briefly summarize the overall efficacy of TCM in the treatment of MN, with no systematic and specialized collation of the targeted mechanisms through which TCM regulates different PCD subtypes in MN. This research gap greatly restricts the in-depth exploration of the underlying pathological mechanisms. Therefore, targeting this critical research gap, this narrative review systematically summarizes the current progress of TCM in the treatment of MN via modulation of PCD mechanisms. First, we systematically delineate the activation and regulatory patterns of diverse PCD modalities in MN. We then comprehensively summarize the molecular mechanisms through which TCM formulas, herbal extracts, and bioactive ingredients intervene in PCD to protect against MN. Finally, we critically evaluate the available clinical evidence, current research limitations, and future developmental directions, with the ultimate goal of providing rational strategies for mechanism-driven drug discovery and optimized combination therapy against MN. Methodology Literature Search A comprehensive literature search was systematically performed across PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases. The search strategy employed the following key terms: “membranous nephropathy”, “podocyte”, “programmed cell death”, “apoptosis”, “pyroptosis”, “ferroptosis”, “necroptosis”, “autophagy”, “traditional Chinese medicine”, “herbal compound”, “TCM formulas”, “TCM extracts”, and “active ingredient”. Inclusion Criteria Studies were eligible for inclusion if they investigated the regulatory effects of TCM compounds, herbal extracts, or active ingredients on PCD in both in vivo and in vitro models of MN. Eligible study designs comprised experimental studies, clinical trials, and systematic reviews. Exclusion Criteria Articles were excluded if they were narrative reviews, conference abstracts, case reports, letters, or expert opinions; duplicate publications; or studies with unavailable full text, incomplete data, or irrelevant outcomes. Results Literature retrieval and screening were independently conducted by two investigators in strict accordance with the predefined inclusion and exclusion criteria. Ultimately, 41 eligible studies focusing on TCM-mediated regulation of PCD in MN were enrolled for systematic analysis and synthesis. Regulation Mechanism of PCD in MN PCD‑driven podocyte damage and progressive loss represent a core pathological mechanism underlying sustained proteinuria and renal function decline in MN.15,28 Systematic elucidation of the activation patterns and signaling networks governing PCD in podocytes is therefore critically important for halting podocyte depletion and slowing MN progression (Figure 1). Figure 1Regulatory mechanisms of programmed cell death in membranous nephropathy podocytes. Upstream signals including complement-dependent and complement-independent pathways trigger key cellular events, which converge to regulate apoptosis, pyroptosis, ferroptosis, and autophagy. Dysregulation of these PCD processes drives podocyte loss, glomerular barrier damage, proteinuria, and progressive renal injury in membranous nephropathy. Solid arrow = activation, T-bar arrow = inhibition.The pathway diagram outlines programmed cell death in membranous nephropathy podocytes, split into complement-dependent and independent pathways. The complement-dependent pathway involves sublytic C5b-9, while the independent pathway includes anti-PLA2R antibodies, TRPC6, PM2.5, sPLA2IB and ncRNAs dysregulation. Key events are DNA damage, calcium influx, ROS burst, cytokine and protease release, ER stress, mitochondrial and lysosome dysfunction. Four processes are detailed: 1. Apoptosis via PI3K/Akt/mTOR and caspase pathways. 2. Pyroptosis via TRAF6, TAK1, PI3K, Akt and NLRP3 inflammasome leading to caspase-1 activation. 3. Ferroptosis involving iron overload, lipid peroxidation, JNK and FoxO1 pathways. 4. Autophagy via MAPK, AMPK, mTOR, regulating autophagy levels. Outcomes include podocyte loss, glomerular barrier destruction, proteinuria, renal fibrosis and progressive renal injury.Diagram of programmed cell death regulation in membranous nephropathy: apoptosis, pyroptosis, ferroptosis, autophagy.Abbreviations: MN, membranous nephropathy; PLA2R, phospholipase A2 receptor; C5b-9, complement membrane attack complex; TRPC6, transient receptor potential canonical 6; sPLA2IB, secretory phospholipase A2 IB; ncRNA, non-coding RNA; p53, tumor protein p53; GADD45, growth arrest and DNA damage-inducible 45; ERK1, extracellular regulated protein kinase 1; ERK2, extracellular regulated protein kinase 2; NOX, NADPH oxidase; ROS, reactive oxygen species; O2, superoxide anion radical; OH, hydroxyl radical; H2O2, hydrogen peroxide; ER, endoplasmic reticulum; GRP78, glucose-regulated protein 78; PERK, protein kinase RNA-like ER kinase; CHOP, C/EBP homologous protein; ΔΨm, mitochondrial membrane potential; Cyt c, cytochrome c; AIF, apoptosis-inducing factor; Apaf-1, apoptotic protease activating factor 1; PI3K/Akt/mTOR, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin; NLRP3, NOD-like receptor thermal protein domain-associated protein 3; GSDMD, Gasdermin D; N-GSDMD, Gasdermin D N-terminal fragment; IL-1β, interleukin-1β; IL-18, interleukin-18; Nrf2/HO-1, nuclear factor erythroid 2-related factor 2/heme oxygenase-1; JNK, c-Jun N-terminal kinase; ACSL4, acyl-CoA synthetase long-chain family member 4; GPX4, glutathione peroxidase 4; AMPK, adenosine monophosphate-activated protein kinase; ULK1, unc-51-like autophagy activating kinase 1; LC3, microtubule-associated protein light chain 3; p62, sequestosome 1; miR, microRNA; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; Ang II, angiotensin II; TNF, tumor necrosis factor; Caspase, cysteinyl aspartate protease; Beclin1, autophagy-related Beclin-1 protein. Regulatory mechanisms of programmed cell death in membranous nephropathy podocytes. Upstream signals including complement-dependent and complement-independent pathways trigger key cellular events, which converge to regulate apoptosis, pyroptosis, ferroptosis, and autophagy. Dysregulation of these PCD processes drives podocyte loss, glomerular barrier damage, proteinuria, and progressive renal injury in membranous nephropathy. Solid arrow = activation, T-bar arrow = inhibition. Upstream Initiating Signals of PCD in Podocytes As noted above, sublytic C5b-9 represents the primary initiating trigger of podocyte injury in MN. Upon insertion into the podocyte membrane, this complex initiates a cascade of intracellular signaling events rather than merely forming pores and disrupting membrane integrity.29 C5b-9 directly induces podocyte DNA damage,11 triggers NADPH oxidase‑dependent reactive oxygen species (ROS) bursts,30 and stimulates the production of proteases, cytokines, extracellular matrix components, and oxidants.31,32 Moreover, C5b-9 targets mitochondria, endoplasmic reticulum, and lysosomes to induce mitochondrial dysfunction, endoplasmic reticulum stress (ERS), and blockade of the lysosome‑dependent autophagic pathway.10,33–36 Notably, complement‑independent pathways can also independently initiate PCD in MN. These include anti‑PLA2R antibody production,37 activation of group IB secretory phospholipase A2 (sPLA2IB),38 angiotensin II (Ang II)‑mediated upregulation of transient receptor potential ion channel 6 (TRPC6) leading to calcium overload,39 PM2.5 exposure,40 dysregulated non‑coding RNAs (ncRNAs),41 and urokinase plasminogen activator (uPA) deficiency.42 Complement‑dependent and complement‑independent pathways act either independently or synergistically to amplify pathological responses and collectively drive PCD progression in MN. Activation and Regulatory Mechanisms of PCD in MN During MN pathogenesis, podocytes undergo distinct PCD phenotypes depending on stimulus intensity, duration, and intracellular context. The regulatory mechanisms of each PCD subtype are summarized below. Apoptosis Apoptosis is one of the best‑characterized forms of PCD in MN, defined by nuclear pyknosis, apoptotic body formation, and minimal inflammatory reactions.43 It is primarily executed by the caspase family and occurs via two distinct cascades: the extrinsic death receptor pathway and the intrinsic mitochondrial pathway.43,44 The extrinsic pathway is initiated by death receptor‑ligand interactions leading to caspase‑8 activation. The intrinsic pathway is driven by mitochondrial membrane permeabilization induced by calcium dyshomeostasis and oxidative stress, and is tightly regulated by the BCL‑2 family, including anti‑apoptotic (BCL‑2, BCL‑XL) and pro‑apoptotic (BAX, BAK) members. Both pathways converge on the activation of effector caspases‑3/7. In MN, podocyte apoptosis directly causes irreversible podocyte depletion and glomerular filtration barrier disruption, resulting in massive proteinuria and progressive renal dysfunction. Biopsy and animal studies confirm that the extent of podocyte apoptosis correlates strongly with proteinuria severity and MN progression.45 Multiple signaling pathways govern podocyte apoptosis in MN. In the complement‑dependent pathway, C5b-9 promotes apoptosis via the C-X-C motif chemokine ligand 12/C-X-C chemokine receptor type 4/ Signal transducer and activator of transcription 3(CXCL12/CXCR4/STAT3) axis, and CXCL12 silencing alleviates C5b-9‑induced podocyte damage.46 In complement‑independent signaling, oxidative stress triggers apoptosis through the Mothers against decapentaplegic homolog 3/Protein kinase A/NADPH oxidase 4(Smad3/PKA/NOX4) pathway.47 sPLA2IB‑activated PLA2R induces both mitochondrial and death receptor apoptotic cascades via the Phosphoinositide 3-kinase/Protein kinase B/Mammalian target of rapamycin(PI3K/Akt/mTOR) axis.38 The Extracellular signal-regulated kinase 1/2/Y-box binding protein 1/Phospholipase A2 receptor 1(ERK1/2/YB‑1/PLA2R1) axis suppresses apoptosis by reducing PLA2R1 expression.48 The Caveolin-1 (CAV1)/PKA/Dynamin-related protein 1(DRP1) pathway, which mediates mitochondrial dysfunction, also contributes to apoptosis; canagliflozin inhibits this pathway to stabilize mitochondrial potential, downregulate pro‑apoptotic proteins, and upregulate anti‑apoptotic factors.49 A critical regulatory network for podocyte apoptosis in MN is constituted by ncRNAs. CircRNAs including circ_000052450 and circ_CDYL51 promote Ang II‑induced apoptosis via miR‑500a‑5p/C-X-C motif chemokine ligand 16(CXCL16) and miR‑149‑5p/TNF superfamily member 11(TNFSF11), respectively. In contrast, miRNAs such as miR‑130a‑5p,52 miR-186,53 miR-423-5p54 and miR-193a55 attenuate apoptosis by targeting PLA2R, P2X7, and WT1/β‑catenin. The lncRNA XIST promotes apoptosis via the miR‑217‑Toll-like receptor 4(TLR4) pathway, and its inhibition alleviates Ang II‑induced injury.56 miR‑206‑3p targets WT1 and activates the C‑MIP/nephrin/PI3K pathway to exacerbate apoptosis.57 Collectively, podocyte apoptosis in MN is synergistically regulated by pathogenic antigen pathways, mitochondrial signaling, and ncRNA networks. Targeting these nodes may enable precise therapeutic intervention in MN. Pyroptosis Pyroptosis is a pro‑inflammatory form of PCD driven by inflammasomes and inflammatory caspases. It is defined by GSDMD‑mediated membrane pore formation and release of IL‑1β and IL‑18, and is widely implicated in the progression of chronic kidney disease.58 In MN, complement activation, oxidative stress, and danger‑associated molecular patterns cooperatively activate the NOD-Like Receptor Family Pyrin Domain Containing 3(NLRP3) inflammasome, promoting caspase‑1‑dependent cleavage of GSDMD. This leads to membrane rupture, cytosolic leakage, and robust release of IL‑1β and IL‑18, which further amplify local inflammation, disrupt glomerular homeostasis, and promote renal fibrosis. Pyroptosis also crosstalks extensively with apoptosis to accelerate podocyte loss and chronic renal failure.59 Notably, the NLRP3 inflammasome is also involved in glucocorticoid resistance in idiopathic MN (IMN), suggesting that pyroptosis targeting may overcome treatment resistance.60 Pyroptosis activation is controlled by multiple signaling cascades. Complement stimulation induces pyroptosis by triggering mitochondrial dysfunction and ROS production, and ROS inhibition reverses complement‑mediated pyroptotic damage.10 Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) is overexpressed in MN and activates the GSDMD/caspase‑1 pathway via Transforming Growth Factor-beta-Activated Kinase 1 (TAK1) ubiquitination, representing a core regulatory node.61 Benzo[b]fluoranthene, a PM2.5 component, induces pyroptosis via the PI3K/Akt pathway.40 The NLRP3‑ASC‑caspase‑1/IL‑18/GSDMD axis is aberrantly activated in MN podocytes, and disulfiram (DSF) attenuates pyroptosis and renal injury by inhibiting this pathway and GSDMD membrane translocation.13 In summary, podocyte pyroptosis in MN is driven by complement injury, oxidative stress, and the PI3K/Akt, TRAF6/TAK1, and NLRP3 signaling axes. Targeted inhibition of pyroptosis represents a promising therapeutic strategy for MN. Ferroptosis Ferroptosis is an iron‑dependent form of PCD driven by excessive lipid peroxidation, characterized by disrupted iron metabolism, impaired antioxidant defense, and mitochondrial dysfunction. It is increasingly recognized as a key pathogenic mechanism in various renal diseases.62 The central mechanism of ferroptosis involves the Glutathione Peroxidase 4(GPX4)‑mediated detoxification of lipid peroxides using Glutathione(GSH) generated via System Xc−‑mediated cysteine uptake. Inhibition of System Xc− or GPX4 leads to lipid peroxide accumulation and ferroptotic cell death.63 In MN, ferroptosis causes lipid peroxidative damage to podocyte membranes and mitochondrial structural collapse, thereby worsening filtration dysfunction and proteinuria. Lipid peroxidation products further trigger inflammation and immune imbalance to promote renal fibrosis.64 Studies in the passive Heymann nephritis (PHN) model confirm that ferroptosis contributes to MN pathogenesis, accompanied by ferritinophagy activation. This is manifested by elevated renal Fe2⁺ and Malondialdehyde(MDA), decreased Superoxide Dismutase(SOD), GSH, and GPX4, and upregulated Transferrin Receptor(TFR), Acyl-CoA Synthetase Long-Chain Family Member 4(ACSL4), and ferritinophagy markers.16 Bioinformatics analysis identifies seven ferroptosis‑related genes including Nuclear Receptor Subfamily 1 Group D Member 1(NR1D1) and YTH Domain Containing 2(YTHDC2) as potential MN biomarkers, with their dysregulation associated with immune cell infiltration.65 Recent evidence demonstrates that podocyte ferroptosis in MN is modulated by ERS and the JNK(c-Jun N-terminal Kinase)/FoxO1(Forkhead Box O1)/GPX4 axis.66,67 The Nrf2/HO‑1(Heme Oxygenase 1) antioxidant pathway acts as a key upstream regulator; ferroptosis inhibition markedly activates Nrf2/HO‑1 to reduce iron deposition, lipid peroxidation, and pathological injury, whereas Nrf2 blockade abolishes these renoprotective effects.68 Although research is still emerging, ferroptosis is firmly established as a key mediator of podocyte injury and MN progression, representing a highly promising research and therapeutic direction. Autophagy Autophagy is a conserved catabolic process whereby cells degrade cytoplasmic proteins and damaged organelles via lysosomes under the control of autophagy‑related genes. Key proteins including Beclin‑1 and Microtubule-associated protein 1 light chain 3(LC3) mediate autophagosome formation and maturation. Autophagy clears cytotoxic proteins and maintains cellular homeostasis to counteract cell death and inflammation, making it a critical therapeutic target in renal disease.69,70 Under physiological conditions, podocyte autophagy is indispensable for glomerular filtration barrier integrity. In MN, however, autophagy becomes dysregulated: either insufficient or excessive autophagy exacerbates podocyte injury, accelerates disease progression, and correlates with proteinuria severity and clinical outcomes.71,72 Clinical studies demonstrate that autophagosome numbers are significantly reduced in MN patients, and the reduction worsens with pathological stage in IMN.73,74 Autophagy also exerts a reparative role by alleviating ERS‑induced podocyte injury during MN progression.75 Complement activation and ncRNAs are major triggers of autophagic dysfunction in MN. Complement disrupts lysosomal membrane integrity to block the lysosome‑dependent autophagic pathway and worsen apoptosis.34,76 miR‑664a‑5p targets Homeodomain-interacting protein kinase 2(HIPK2), upregulates Calpain1, cleaves GSα, inhibits autophagy, and promotes MN progression.14 Of note, the ubiquitin–proteasome system (UPS) becomes overloaded and decompensated in podocytes, leading to toxic protein accumulation and activation of the autophagosome–lysosome system.77 Podocyte autophagy in MN is regulated by multiple pathways, with mTOR signaling as the central axis. sPLA2‑IB binds to PLA2R and activates the p38 mitogen-activated protein kinase(p38MAPK)/mTOR/Unc-51 like autophagy activating kinase 1(ULK1) pathway to suppress autophagy and aggravate injury; this effect is reversed by p38 inhibitors.78 Rapamycin enhances autophagy, reduces apoptosis, and alleviates podocyte damage by inhibiting the mTOR‑ULK1 and mTOR/Ribosomal protein S6 kinase beta-1(P70S6K)/Eukaryotic translation initiation factor 4E-binding protein 1(4EBP1) pathways.79,80 Metformin plus rapamycin activates the AMP-activated protein kinase(AMPK)/mTOR pathway, increases autophagic protein expression, and ameliorates proteinuria and renal fibrosis in IMN.81 Other regulatory pathways include ERK1/2, Wingless-related integration site(Wnt)/β‑catenin, and PI3K/Akt. TRPC6 inhibits autophagy via ERK1/2 phosphorylation to promote C5b‑9‑induced injury.82 C5b‑9 activates the Wnt/β‑catenin pathway to enhance autophagy, and pathway inhibition reduces autophagy and attenuates podocyte damage.83 Na⁺/H⁺ exchanger‑1 (NHE‑1) activates autophagy via PI3K/Akt to alleviate ERS‑induced cytoskeletal injury.75,84 Autophagy is also modulated by the immune microenvironment: Th1/Th2 imbalance stimulates IgG1 overproduction by B cells to suppress autophagy and exacerbate renal injury.85 In conclusion, dysregulated autophagy acts as one of the core mechanisms underlying podocyte injury in MN. Molecular Mechanism of TCM Regulating PCD in MN Diverse signaling pathways and key molecular nodes collectively constitute an intricate regulatory network governing the aforementioned PCD processes. Owing to its multi-component, multi-target, and holistic regulatory properties, TCM exhibits unique advantages in modulating PCD in MN, ultimately repairing the glomerular filtration barrier and alleviating proteinuria (Figure 2 and Table 1). Table 1Regulatory Effects of TCM on Different PCD Types in MNPCD TypeTCM Formula/Extracts/Active IngredientVivoDoseVitroSignaling PathwayRegulation TargetsRef.ApoptosisQilong Tongshen FormulaC-BSA3.6, 7.2, 14.4 g/kg/-↑:Nephrin, Bcl-2↓:Bax[86]Modified qihuang decoctionC-BSA4, 8 mg/kg/-↑:WT-1, Bcl-2↓:Bax[87]Shenqi Zhilong decoctionC-BSA12.24 g/kg/-↑:Bcl-2↓:Bax, caspase-3[88]Water extract of Wenyang Lishui DecoctionC-BSA16.5 g/kgPodocyte cells-↑:Bcl-2↓:p53[89]Kemeng FangC-BSA3.3075, 6.615, 13.23 g/kg/PI3K/Akt↑:PI3K, PIK3CA, Akt, P-Akt, P-BAD, Bcl-2↓:Bad, Bax, C-caspase3[90]Sanqi oral solutionPHN12.6 mg/kgPodocyte cellsNrf2/HO-1↑:Bcl-2, HO-1, total Nrf2, nuclear Nrf2↓:Bax, Cleaved Caspase-3/Caspase-3, Bax/Bcl-2[91]TetrandrinePHN20 mg/kg/PI3K/Akt↑:p-Bad, Bcl-2↓:p-PI3K, PI3K, Akt, p-Akt[92]Alkaloids of Aristonia Scholaris (picrinine, vallesamine, scholaricine, and 19-epi-scholaricine)CBS-A1 mg/kgMPC5ARNTL/Akt/mTOR↑:ARNTL, CRY1, Bcl-2, NPHS2↓:p-Akt, p-mTOR, HSP90AA1, IgG, IL-6[93]CrocinPHN0.5 mL/100 g/SIRT1/Nrf2/HO-1↑:Bcl-2, Sirt1, Nrf2, HO-1↓:Bax, cleaved caspase-3[94]TetramethylprazineCBS-A100 mg/kg/ERK/cPLA2↑:Bcl-2↓:Bax, p-ERK1/2, p-cPLA2[95]AllicinCBS-A5, 10, 20 mg/kg/TLR4/NF-κB↑:Bcl-2↓:TLR4, p-NF-κB, p65/NF-κB p65, Bax, cleaved caspase‑3/caspase‑3[96]PyroptosisZhen Wu TangC-BSA4.2, 8.4, 16.8 g/kgPodocytes cellNF-κB/NLRP3↓:NLRP3, Caspase-1, IL-1β, p-p65, p-IκBα[97]SulforaphanePHN5 mg/kg/NF-κB p65/Nrf2↓:GSDMD, NLRP3, ASC, caspase-1, IL-1β, IL-18, p-NF-κB p65, NF-κB p65, nuclear Nrf2, nuclear NF-κB p65, nuclear p-NF-κB p65[98]Baicalin//AB8/13 cells stimulated by angiotensin IITNF-α/Caspase-1/GSDMD↑:TGF-β, IL-10↓:Caspase-1, GSDMD-N, TNF-α, IL-8[99]FerroptosisSanqi Qushi formula(Baicalein, Paeoniflorin)PHN21.2, 10.6, 5.3 g/kgMPC-5JNK/FoxO1↑:Synaptopodin, WT-1, α-actinin-4, Nephrin, GPX4, xCT, Total FoxO1, p-FoxO1↓:Desmin, ACSL4, Nuclear FoxO1, p-JNK[66]Sanqi Qushi formulaPHN5.3, 10.6, 21.2 g/kgMPC-5Endoplasmic reticulum stress-ferroptosis↑:Nephrin, Synaptopodin, Podocin, α-actinin-4, WT-1, GPX4, xCT↓:Desmin, ACSL4, CHAC1, GRP78, p-PERK, p-eIF2α, ATF4, CHOP[67]AutophagyShenqi granule//Puromycin aminonucleoside-induced MPC5 cellsmTOR/ULK1↑:ɑ-actinin-4, CD2AP, Beclin1, LC3 II/I↓:p-mTOR, p-ULK1[100]Fangji Huangqi DecoctionPHN0.29 and 0.58 g/kgPodocytes cellsBNIP3↓:P62↑:BNIP3, LC3 II/LC3 I[101]Shen-Qi-Di-Huang decoctionPHN0.3, 0.6, 2 g/kgMPC5USP14/Beclin1↑:LC3 II/I, Beclin1↓:USP14, P62[102]Shendi GranuleC-BSA4 g/kg/Endoplasmic Reticulum Stress↑:Nephrin, Podocalyxin, Beclin1, LC3-II/LC3-I↓:GRP78, CHOP[103]MadecassosidePHN30 mg/kg/AMPK/mTOR↑:p-AMPK, Nephrin, podocin, Synaptopodin, Beclin-1, LC3I/II, p62↓:p-mTOR[104]Total glucosides of paeonyC-BSA100, 200 mg/kg/PI3K/Akt/mTOR↑:Synaptopodin, Beclin1, LC3↓:Desmin, PI3K, p-Akt, mTOR[105]Salvianolic acid BC-BSA100 mg/kgHuman mesangial cellsmiRNA-145-5p/PI3K/Akt↑:miR-145-5p, beclin1, LC3B↓:PI3K, P-Akt, IL-1β, IL-2, IL-6, TNF-α[106]Multiple PCD processesCurcuminPHN300 mg/kg/PI3K/mTOR/Nrf2/HO-1↑:Bcl-2, beclin1, LC3 II/I, Nrf2, HO-1↓:Bax, Caspase-3, PI3K, p-mTOR[107]Mahuang Fuzi and Shenzhuo DecoctionPHN1 mL/100 g/IL-6/STAT3Wnt/β-catenin↑:Synaptopodin, Podocin, Nephrin, Bcl-2, LC3-II↓:pSTAT, p62, β-catenin, GSK-3β[108,109]Modified ShengjiangSanC-BSA27.3 mg/kg/HIF-1α/NOX4Notch1/Hes1PI3K/Akt/mTOR↑:Bcl-xl, Bcl-2, LC3, Beclin1↓:HIF-1α, NOX4, Bax, Bim, Notch1, Hes1, p-PI3K, p-Akt, p-mTOR[110–112]Jiangzhi Tongluo SoftCapsuleC-BSA25, 50, 100 mg/kg/SIRT1/FoxO3AMPK/mTOR↑:Bcl-2, SIRT1, Nephrin, Podocin, p-AMPK/AMPK, LC3, Beclin-1↓:Bax, Bad, FoxO3, p-mTOR/mTOR, p-S6K/S6K, P62[113,114]Yishen TongluoFormulaC-BSA6.61, 13.22, 26.44 g/kg/GRP78/PERK/CHOPmiR-514a-5p/TNFSF15BNIP3↑:Nephrin, Podocin, Podocalyxin, Synaptopodin, TNFSF15, Bax, BAD, LC3II/LC3I, Beclin-1, BNIP3, HIF-1α↓:GRP78, PERK, CHOP, Casepase-3, Bcl-2, Bcl-XL, miR-514a-5p[115–117]Compound ShelongCapsuleC-BSA1.5 g/kg/Bcl-2/Bax/Caspase-3 NLRP3/Caspase-1/IL-1β↑:Nephrin, Podocin, Bcl-2↓:Bax, Caspase-3, NLRP3, Caspase-1, IL-1β, GSDMD[118,119]Jianpi Qushi Heluo formulaPHN16.2, 32.4 g/kg/PINK1/Parkin↑:Mito--Parkin, PINK1, LC3-I/II, Nephrin↓:Cyto-Parkin, P62, Cytc, cleaved caspase-3, caspase-1, NLRP3, IL-1β, IL-6[120,121]Salvia miltiorrhizaPolyphenolateC-BSA16.7, 33.3, 66.7 mg/kg/PERK/ATF4/CHOPAMPK/Sirt1/PGC-1α NLRP3/Caspase-1/GSDMD↑:Bcl-2, p-AMPK/AMPK, p-Sirt1/Sirt1, PGC-1α, Bcl-2, Beclin-1, LC3II↓:PERK, ATF4, CHOP, Bax, NLRP3, Caspase-1, GSDMD, IL-1β, IL-18, Bax, Caspase-7, p62[122–124]Notes: Footnotes: ↑, upregulation/increase; ↓, downregulation/decrease. Figure 2Molecular mechanisms of traditional Chinese medicines (TCM) regulating programmed cell death in membranous nephropathy. This diagram illustrates how TCM formulas (blue labels), extracts (purple labels), and bioactive compounds (green labels) target core signaling pathways to modulate apoptosis, autophagy, ferroptosis, and pyroptosis in podocytes and renal tissue. TCM interventions converge on key molecular nodes including PI3K/Akt, Nrf2/HO-1, AMPK/mTOR, NLRP3 inflammasome, and GPX4 to maintain podocyte homeostasis, reduce proteinuria, and attenuate glomerular injury in membranous nephropathy. Solid arrow = activation, T-bar arrow = inhibition.The diagram illustrates the molecular mechanisms of traditional Chinese medicines (TCM) in regulating programmed cell death in membranous nephropathy. It shows how TCM formulas, extracts and bioactive compounds target core signaling pathways to modulate apoptosis, autophagy, ferroptosis and pyroptosis in podocytes and renal tissue. Key pathways include PI3K/Akt, Nrf2/HO-1, AMPK/mTOR, NLRP3 inflammasome and GPX4. Solid arrows indicate activation, while T-bar arrows indicate inhibition. The diagram highlights the role of compounds like tetrandrine, tetramethylpyrazine, crocin, allicin and sulforaphane in these processes. It also shows the involvement of signaling molecules such as ERK, cPLA2, SIRT1 and NF-kappa B p65. The diagram emphasizes the holistic regulatory properties of TCM in maintaining podocyte homeostasis, reducing proteinuria and attenuating glomerular injury.Molecular mechanisms of traditional Chinese medicines regulating programmed cell death in membranous nephropathy.Abbreviations: KMF, Kemeng Fang; QTF, Qilong Tongshen Formula; MQD, Modified qihuang decoction; SZD, Shenqi Zhilong decoction; WLF, Wenyang Lishui Decoction; FHD, Fangji Huangqi Decoction; SQG, Shenqi granule; SQQS, Sanqi Qushi formula; SOS, Sanqi oral solution; SDG, Shendi Granule; ZWT, Zhen-wu-tang; SQDHD, Shen-Qi-Di-Huang decoction; PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; Bad, Bcl-2-associated agonist of cell death; Bax, Bcl-2-associated X protein; Bak, Bcl-2 homologous antagonist/killer; Bcl-2, B-cell lymphoma 2; ERK, extracellular regulated protein kinase; cPLA2, cytosolic phospholipase A2; Nrf2, nuclear factor erythroid 2-related factor 2; KEAP1, Kelch-like ECH-associated protein 1; Ub, ubiquitin; SIRT1, silent information regulator 1; ARE, antioxidant response element; MAF, musculoaponeurotic fibrosarcoma oncogene homolog; HO-1, heme oxygenase-1; NF-κB, nuclear factor-κB; TLR, Toll-like receptor; JNK, c-Jun N-terminal kinase; ARNTL, aryl hydrocarbon receptor nuclear translocator-like protein 1; FOXO1, forkhead box O1; GPX4, glutathione peroxidase 4; GRP78, glucose-regulated protein 78; CHOP, C/EBP homologous protein; ERS, endoplasmic reticulum stress; AMPK, adenosine monophosphate-activated protein kinase; ULK1, unc-51-like autophagy activating kinase 1; Beclin-1, autophagy-related Beclin-1 protein; K63, K63-linked ubiquitination; NLRP3, NOD-like receptor thermal protein domain-associated protein 3; IL-1β, interleukin-1β; IL-18, interleukin-18; miR-145-5p, microRNA-145-5p. Table 1Regulatory Effects of TCM on Different PCD Types in MNPCD TypeTCM Formula/Extracts/Active IngredientVivoDoseVitroSignaling PathwayRegulation TargetsRef.ApoptosisQilong Tongshen FormulaC-BSA3.6, 7.2, 14.4 g/kg/-↑:Nephrin, Bcl-2↓:Bax[86]Modified qihuang decoctionC-BSA4, 8 mg/kg/-↑:WT-1, Bcl-2↓:Bax[87]Shenqi Zhilong decoctionC-BSA12.24 g/kg/-↑:Bcl-2↓:Bax, caspase-3[88]Water extract of Wenyang Lishui DecoctionC-BSA16.5 g/kgPodocyte cells-↑:Bcl-2↓:p53[89]Kemeng FangC-BSA3.3075, 6.615, 13.23 g/kg/PI3K/Akt↑:PI3K, PIK3CA, Akt, P-Akt, P-BAD, Bcl-2↓:Bad, Bax, C-caspase3[90]Sanqi oral solutionPHN12.6 mg/kgPodocyte cellsNrf2/HO-1↑:Bcl-2, HO-1, total Nrf2, nuclear Nrf2↓:Bax, Cleaved Caspase-3/Caspase-3, Bax/Bcl-2[91]TetrandrinePHN20 mg/kg/PI3K/Akt↑:p-Bad, Bcl-2↓:p-PI3K, PI3K, Akt, p-Akt[92]Alkaloids of Aristonia Scholaris (picrinine, vallesamine, scholaricine, and 19-epi-scholaricine)CBS-A1 mg/kgMPC5ARNTL/Akt/mTOR↑:ARNTL, CRY1, Bcl-2, NPHS2↓:p-Akt, p-mTOR, HSP90AA1, IgG, IL-6[93]CrocinPHN0.5 mL/100 g/SIRT1/Nrf2/HO-1↑:Bcl-2, Sirt1, Nrf2, HO-1↓:Bax, cleaved caspase-3[94]TetramethylprazineCBS-A100 mg/kg/ERK/cPLA2↑:Bcl-2↓:Bax, p-ERK1/2, p-cPLA2[95]AllicinCBS-A5, 10, 20 mg/kg/TLR4/NF-κB↑:Bcl-2↓:TLR4, p-NF-κB, p65/NF-κB p65, Bax, cleaved caspase‑3/caspase‑3[96]PyroptosisZhen Wu TangC-BSA4.2, 8.4, 16.8 g/kgPodocytes cellNF-κB/NLRP3↓:NLRP3, Caspase-1, IL-1β, p-p65, p-IκBα[97]SulforaphanePHN5 mg/kg/NF-κB p65/Nrf2↓:GSDMD, NLRP3, ASC, caspase-1, IL-1β, IL-18, p-NF-κB p65, NF-κB p65, nuclear Nrf2, nuclear NF-κB p65, nuclear p-NF-κB p65[98]Baicalin//AB8/13 cells stimulated by angiotensin IITNF-α/Caspase-1/GSDMD↑:TGF-β, IL-10↓:Caspase-1, GSDMD-N, TNF-α, IL-8[99]FerroptosisSanqi Qushi formula(Baicalein, Paeoniflorin)PHN21.2, 10.6, 5.3 g/kgMPC-5JNK/FoxO1↑:Synaptopodin, WT-1, α-actinin-4, Nephrin, GPX4, xCT, Total FoxO1, p-FoxO1↓:Desmin, ACSL4, Nuclear FoxO1, p-JNK[66]Sanqi Qushi formulaPHN5.3, 10.6, 21.2 g/kgMPC-5Endoplasmic reticulum stress-ferroptosis↑:Nephrin, Synaptopodin, Podocin, α-actinin-4, WT-1, GPX4, xCT↓:Desmin, ACSL4, CHAC1, GRP78, p-PERK, p-eIF2α, ATF4, CHOP[67]AutophagyShenqi granule//Puromycin aminonucleoside-induced MPC5 cellsmTOR/ULK1↑:ɑ-actinin-4, CD2AP, Beclin1, LC3 II/I↓:p-mTOR, p-ULK1[100]Fangji Huangqi DecoctionPHN0.29 and 0.58 g/kgPodocytes cellsBNIP3↓:P62↑:BNIP3, LC3 II/LC3 I[101]Shen-Qi-Di-Huang decoctionPHN0.3, 0.6, 2 g/kgMPC5USP14/Beclin1↑:LC3 II/I, Beclin1↓:USP14, P62[102]Shendi GranuleC-BSA4 g/kg/Endoplasmic Reticulum Stress↑:Nephrin, Podocalyxin, Beclin1, LC3-II/LC3-I↓:GRP78, CHOP[103]MadecassosidePHN30 mg/kg/AMPK/mTOR↑:p-AMPK, Nephrin, podocin, Synaptopodin, Beclin-1, LC3I/II, p62↓:p-mTOR[104]Total glucosides of paeonyC-BSA100, 200 mg/kg/PI3K/Akt/mTOR↑:Synaptopodin, Beclin1, LC3↓:Desmin, PI3K, p-Akt, mTOR[105]Salvianolic acid BC-BSA100 mg/kgHuman mesangial cellsmiRNA-145-5p/PI3K/Akt↑:miR-145-5p, beclin1, LC3B↓:PI3K, P-Akt, IL-1β, IL-2, IL-6, TNF-α[106]Multiple PCD processesCurcuminPHN300 mg/kg/PI3K/mTOR/Nrf2/HO-1↑:Bcl-2, beclin1, LC3 II/I, Nrf2, HO-1↓:Bax, Caspase-3, PI3K, p-mTOR[107]Mahuang Fuzi and Shenzhuo DecoctionPHN1 mL/100 g/IL-6/STAT3Wnt/β-catenin↑:Synaptopodin, Podocin, Nephrin, Bcl-2, LC3-II↓:pSTAT, p62, β-catenin, GSK-3β[108,109]Modified ShengjiangSanC-BSA27.3 mg/kg/HIF-1α/NOX4Notch1/Hes1PI3K/Akt/mTOR↑:Bcl-xl, Bcl-2, LC3, Beclin1↓:HIF-1α, NOX4, Bax, Bim, Notch1, Hes1, p-PI3K, p-Akt, p-mTOR[110–112]Jiangzhi Tongluo SoftCapsuleC-BSA25, 50, 100 mg/kg/SIRT1/FoxO3AMPK/mTOR↑:Bcl-2, SIRT1, Nephrin, Podocin, p-AMPK/AMPK, LC3, Beclin-1↓:Bax, Bad, FoxO3, p-mTOR/mTOR, p-S6K/S6K, P62[113,114]Yishen TongluoFormulaC-BSA6.61, 13.22, 26.44 g/kg/GRP78/PERK/CHOPmiR-514a-5p/TNFSF15BNIP3↑:Nephrin, Podocin, Podocalyxin, Synaptopodin, TNFSF15, Bax, BAD, LC3II/LC3I, Beclin-1, BNIP3, HIF-1α↓:GRP78, PERK, CHOP, Casepase-3, Bcl-2, Bcl-XL, miR-514a-5p[115–117]Compound ShelongCapsuleC-BSA1.5 g/kg/Bcl-2/Bax/Caspase-3 NLRP3/Caspase-1/IL-1β↑:Nephrin, Podocin, Bcl-2↓:Bax, Caspase-3, NLRP3, Caspase-1, IL-1β, GSDMD[118,119]Jianpi Qushi Heluo formulaPHN16.2, 32.4 g/kg/PINK1/Parkin↑:Mito--Parkin, PINK1, LC3-I/II, Nephrin↓:Cyto-Parkin, P62, Cytc, cleaved caspase-3, caspase-1, NLRP3, IL-1β, IL-6[120,121]Salvia miltiorrhizaPolyphenolateC-BSA16.7, 33.3, 66.7 mg/kg/PERK/ATF4/CHOPAMPK/Sirt1/PGC-1α NLRP3/Caspase-1/GSDMD↑:Bcl-2, p-AMPK/AMPK, p-Sirt1/Sirt1, PGC-1α, Bcl-2, Beclin-1, LC3II↓:PERK, ATF4, CHOP, Bax, NLRP3, Caspase-1, GSDMD, IL-1β, IL-18, Bax, Caspase-7, p62[122–124]Notes: Footnotes: ↑, upregulation/increase; ↓, downregulation/decrease. Regulatory Effects of TCM on Different PCD Types in MN Notes: Footnotes: ↑, upregulation/increase; ↓, downregulation/decrease. Molecular mechanisms of traditional Chinese medicines (TCM) regulating programmed cell death in membranous nephropathy. This diagram illustrates how TCM formulas (blue labels), extracts (purple labels), and bioactive compounds (green labels) target core signaling pathways to modulate apoptosis, autophagy, ferroptosis, and pyroptosis in podocytes and renal tissue. TCM interventions converge on key molecular nodes including PI3K/Akt, Nrf2/HO-1, AMPK/mTOR, NLRP3 inflammasome, and GPX4 to maintain podocyte homeostasis, reduce proteinuria, and attenuate glomerular injury in membranous nephropathy. Solid arrow = activation, T-bar arrow = inhibition. TCM Inhibits Apoptosis of MN TCM compound formulations represent the most commonly applied therapeutic strategy in clinical practice. A growing body of evidence indicates that such formulations modulate apoptosis-related protein expression via multiple signaling axes, thereby stabilizing podocyte structure and exerting potent renoprotective effects in MN. Numerous TCM compounds target the intrinsic apoptotic pathway, modulate Bcl‑2/Bax balance, ameliorate podocyte injury, and upregulate podocyte‑specific markers including Nephrin and Wilms tumor protein 1(WT‑1), thus mitigating disease progression. For instance, Qilong Tongshen Formula,86 modified qihuang decoction,87 Shenqi Zhilong decoction88 and the aqueous extract of Wenyang Lishui Formula89 alleviate podocyte injury via this canonical apoptotic pathway, reduce proteinuria, hypoalbuminemia, and renal dysfunction, and delay pathological deterioration in MN rat models. The PI3K/Akt pathway serves as another crucial axis through which TCM compounds counteract apoptosis. Kemeng Fang (KMF), composed of 13 herbal medicines including Codonopsis Radix and Astragali Radix, exerts the pharmacological effects of activating blood circulation, inducing diuresis, and tonifying the kidney and replenishing qi. It significantly reduces 24‑h urinary protein, serum creatinine, blood urea nitrogen and serum lipid levels in MN rats, while upregulating the expression of podocyte marker proteins Nephrin and WT‑1. Mechanistically, the renoprotective efficacy of KMF is closely mediated by the PI3K/Akt signaling pathway, which downregulates pro‑apoptotic proteins (Bad, Bax, cleaved‑caspase‑3) and elevates the level of the anti‑apoptotic protein Bcl‑2.90 Oxidative stress‑mediated apoptosis is also extensively modulated by TCM compounds. Sanqi Oral Solution (SOS) consists of two medicinal herbs, Astragali Radix and Notoginseng Radix et Rhizoma. It exerts anti‑apoptotic and renoprotective effects via activating the Nrf2/HO‑1 signaling pathway, suppressing the expression of cleaved caspase‑3 and Bax, and reducing the Bax/Bcl‑2 ratio.91 Among TCM extracts and active monomers, the PI3K/Akt pathway remains a common regulatory target. Tetrandrine, a bisbenzylisoquinoline alkaloid extracted from Stephania tetrandra, has been documented to exert extensive biological activities, such as anti-fibrotic, anti-inflammatory, and anti-tumor effects. It markedly inhibits renal apoptosis in PHN rats through the PI3K/Akt signaling pathway.92 Alstonia scholaris is a traditional folk medicinal herb with the effects of clearing heat and detoxifying, and it is rich in a variety of chemical constituents. Alkaloids from Alstonia scholaris (picrinine, vallesamine, scholaricine, 19‑epi‑scholaricine) markedly reduce proteinuria, mitigate glomerular basement membrane thickening and IgG/C3 deposition, alleviate ROS accumulation and inflammation, and inhibit podocyte apoptosis in MN mice. Notably, 19‑epi‑scholaricine exhibits superior therapeutic efficacy relative to prednisone, acting by targeting the circadian rhythm regulator Aryl hydrocarbon receptor nuclear translocator-like protein 1(ARNTL) and inhibiting the Akt/mTOR axis.93 Crocin, an edible glycoside compound extracted from Crocus sativus and Gardenia jasminoides, possesses multiple biological activities and primarily targets the Nrf2 signaling pathway. In PHN rats, crocin markedly decreases serum lipid, serum creatinine, blood urea nitrogen, and urinary albumin levels and ameliorates podocyte loss. Mechanistically, its renoprotective effect is closely attributed to the activation of the Sirtuin 1(SIRT1)/Nrf2/HO-1 signaling cascade, which further suppresses podocyte apoptosis.94 Tetramethylpyrazine is the major active alkaloid derived from the TCM Ligusticum chuanxiong and has been widely applied in clinical practice. It has been proven to exert renoprotective effects in MN rats by inhibiting the ERK/Cytosolic phospholipase A2(cPLA2) signaling pathway, thereby synergistically producing anti-inflammatory and anti-apoptotic activities.95 As a natural plant active monomer, allicin can targeted inhibit the TLR4/NF-κB inflammatory signaling pathway, alleviate cell apoptosis induced by the inflammatory microenvironment, thereby ameliorating renal pathological injury, reducing immune complex deposition, lowering the apoptotic index, and protecting renal function.96 Collectively, TCM compounds, extracts, and active monomers comprehensively balance apoptotic signaling via multiple pathways including the mitochondrial apoptotic cascade, PI3K/Akt, Nrf2/HO‑1, ERK/cPLA2, and TLR4/NF‑κB, thereby inhibiting podocyte apoptosis and restoring the impaired glomerular filtration barrier in MN. TCM Inhibits Pyroptosis of MN In MN, TCM suppresses pyroptosis at multiple stages, including upstream signaling, inflammasome assembly, and downstream effector activation, thereby mitigating renal injury. For example, Zhen Wu Tang, a classical herbal prescription composed of five medicinal herbs including Poria Cocos, Atractylodis Macrocephalae Rhizoma, Aconiti Radix Lateralis Preparata, Zingiberis Rhizoma Recens, and Paeoniae Radix Alba, exerts the effects of warming yang and promoting diuresis. It has long been applied for the clinical management of renal edema. Mechanistically, it inhibits the NF‑κB pathway, blocks NLRP3 inflammasome activation and caspase‑1 expression, and ultimately ameliorates podocyte pyroptosis.97 In terms of TCM monomers, sulforaphane, a natural antioxidant, has beneficial effects on various renal diseases. It can ameliorate oxidative stress as well as subsequent podocyte pyroptosis and the release of inflammatory factors IL-18 and IL-1β via regulating the p-NF-κB p65 and Nrf2 pathways, thereby exerting therapeutic effects on MN.98 Baicalin, a flavonoid compound extracted from the roots of Scutellaria baicalensis, exerts anti-inflammatory, antioxidant and antibacterial properties and serves as one of the crucial bioactive substances responsible for the pharmacological effects of Scutellaria baicalensis. The combination of baicalin and disulfiram can significantly ameliorate angiotensin II–induced podocyte injury. It inhibits the release of pro-inflammatory factors such as TNF-α and IL-8, and simultaneously downregulates the protein expression of caspase-1 and GSDMD-N, thereby suppressing podocyte pyroptosis. This combined treatment exhibits a stronger renoprotective effect than monotherapy.99 These findings indicate that targeting pyroptosis represents a key mechanism underlying the renoprotective effects of TCM, supporting a promising strategy for combined anti‑inflammatory and anti‑pyroptotic intervention in MN. TCM Inhibits Ferroptosis of MN TCM concurrently suppresses the JNK/FoxO1 axis and ERS signaling, thereby blocking ferroptosis activation and preserving podocyte structural integrity. At the compound level, Sanqi Qushi Formula (SQQS), a seven‑herb formulation designed to promote blood circulation, eliminate dampness, and tonify qi, was originally developed by Guangdong Provincial Hospital of Chinese Medicine in 1995 and has been widely utilized for the clinical treatment of glomerulonephritis. Experimental evidence has demonstrated that SQQS ameliorates 24‑h urinary protein, serum albumin, creatinine, and total cholesterol levels in PHN rats, while mitigating glomerular pathological damage and reducing IgG/C3 deposition. Mechanistically, SQQS inhibits the JNK/FoxO1 pathway, reduces FoxO1 nuclear translocation, upregulates GPX4, xCT, GSH, and SOD expression, lowers MDA, ACSL4, and iron levels, relieves mitochondrial damage, and inhibits GPX4‑dependent ferroptosis. These effects are recapitulated in cultured podocytes.66 In parallel, SQQS inhibits ERS signaling by downregulating Glucose-regulated protein 78(GRP78), p‑PERK, Activating transcription factor 4(ATF4), and C/EBP homologous protein(CHOP), thereby blocking ERS‑mediated ferroptosis. Consequently, SQQS stabilizes Nephrin, Podocin, and Synaptopodin expression and mitigates podocyte injury.67 Notably, Baicalein and Paeoniflorin, two key active components of SQQS, directly target JNK1 and upregulate GPX4 to inhibit ferroptosis.66 Nevertheless, the potential synergistic or antagonistic interactions between these two ingredients remain unclear. Clarifying such interplays will facilitate further formulation optimization and novel drug development. Current evidence demonstrates that TCM inhibits podocyte ferroptosis via coordinated regulation of signaling pathways and organelle homeostasis. This multi‑target intervention confers superior podocyte protection compared with single‑pathway inhibitors, providing a feasible TCM‑based strategy for ferroptosis‑driven podocyte injury in MN. TCM Regulates Autophagy of MN In MN, autophagy functions as a critical cyto‑protective mechanism, and its dysregulation strongly influences disease onset, progression, and therapeutic response. TCM modulates and upregulates pro‑survival autophagy in podocytes by targeting autophagy‑related pathways, thereby exerting renoprotective effects. mTOR is a core regulator of autophagy initiation. Shenqi Granule, composed of 13 medicinal herbs including Astragali Radix and Angelicae Sinensis Radix, exerts the efficacy of balancing yin and yang. It has been clinically applied for MN treatment for a long time with definite therapeutic efficacy. It enhances autophagic activity by inhibiting mTOR/ULK1 phosphorylation, increasing Beclin‑1 and Microtubule-associated protein 1 light chain 3 isoform II/I ratio(LC3II/I) expression, and elevating levels of the podocyte cytoskeletal proteins CD2-associated protein(CD2AP) and α‑Actinin‑4.100 Mitophagy, a selective form of autophagy mediated by PTEN-induced putative kinase 1 (PINK1)/Parkin, BCL2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3), and NIP3-like protein X (NIX), is highly active in renal tissue.125, Similar to Zhen Wu Tang, Fangji Huangqi Decoction (FHD) is also an empirical herbal formula widely utilized for the clinical treatment of edema. It enhances BNIP3-mediated mitophagy, stabilizes mitochondrial membrane potential (MMP), and ultimately ameliorates podocyte injury in MN.101 Focusing on the dysregulation mechanism of deubiquitinases, Shen‑Qi‑Di‑Huang Decoction (SQDHD) inhibits ubiquitin‑specific protease 14 (USP14), promotes K63‑linked ubiquitination of Beclin‑1, improves partial podocyte functional status in preclinical models, and alleviates renal injury.102 With regard to the molecular mechanisms governing ERS modulation, Shendi Granule enhances podocyte autophagy and alleviates ERS-associated injury through the GRP78/CHOP signaling cascade, and markedly reduces 24-hour urinary protein excretion, exhibiting superior therapeutic efficacy to valsartan in C-BSA-induced MN rat models.103 Among active monomers, madecassoside (MA), a triterpenoid saponin derived from Centella asiatica, possesses multiple renal protective effects. It has also been proven to activate protective autophagy via the AMPK/mTOR pathway, relieve renal inflammation and oxidative stress, and ameliorate MN‑related injury.104 Total glucosides of paeony, the principal active constituent of Paeonia lactiflora, possesses multiple biological functions, including anti-inflammatory and immunomodulatory activities. In MN, it activates podocyte autophagy via suppressing the PI3K/Akt/mTOR signaling pathway, while ameliorating lipid metabolic disorder and oxidative stress.105 Salvianolic acid B, a natural polyphenolic acid derived from Salvia miltiorrhiza Bunge, possesses multiple biological activities, including antioxidant and cardiovascular protective properties. Experimental evidence has confirmed that it upregulates Beclin‑1 and LC3 expression via the miR‑145‑5p/PI3K/Akt axis, activates renal autophagy, suppresses mesangial cell proliferation and inflammation, and alleviates glomerular injury.106 These findings confirm that regulating autophagy pathways and maintaining autophagic homeostasis represent key mechanisms through which TCM protects podocytes and kidneys in MN. TCM Simultaneously Modulates Multiple PCD Processes Multiple upstream factors (eg, inflammation, oxidative stress, and metabolic disturbance) and signaling pathways converge to regulate diverse PCD processes simultaneously. The pathological progression of MN involves the coordinated dysregulation of multiple PCD modalities, including apoptosis, pyroptosis, ferroptosis, and autophagy.19 Owing to their multi‑component and multi‑target characteristics, many TCM formulations and their active components are capable of simultaneously modulating two or more PCD processes, thereby exerting a holistic regulatory effect on podocyte injury and disease progression in MN (Figure 3). Figure 3TCM simultaneously modulates multiple PCD processes. The diagram illustrates how various TCM formulas, extracts, and active ingredients simultaneously modulate the key PCD modalities (apoptosis, autophagy, mitophagy, and pyroptosis) via core signaling cascades in podocytes during MN pathogenesis. Representative agents are shown, including: (1) Curcumin, Mahuang Fuzi and Shenzhuo Decoction, Modified Shengjiang Tongluo Soft Capsule, Jiangzhi Tongluo Soft Capsule, and Yishen Tongluo Formula, which target apoptosis and autophagy through pathways such as PI3K/Akt/mTOR, Nrf2/HO-1, Wnt/β-catenin, PERK/CHOP, and SIRT1/FoxO3; (2) Salvia miltiorrhiza Polyphenolate, which regulates apoptosis, autophagy, and pyroptosis by modulating the PERK/ATF4/CHOP and AMPK/SIRT1/PGC-1α axes; (3) Jianpi Qushi Heluo Formula, which ameliorates mitophagy dysfunction and subsequent NLRP3 inflammasome‑driven pyroptosis via the PINK1/Parkin pathway; and (4) Compound Shelong Capsule, which inhibits apoptosis and pyroptosis by targeting the Bcl-2/Bax and NLRP3/Caspase-1/GSDMD signaling axes. Collectively, these multi‑target effects of TCM highlight its unique advantage in simultaneously modulating multiple PCD processes and alleviating podocyte injury in MN. Solid arrow = activation, T-bar arrow = inhibition.The diagram illustrates how Traditional Chinese Medicine (TCM) modulates programmed cell death (PCD) processes in podocytes. In the apoptosis and autophagy section, pathways include PI3K/Akt/mTOR, Nrf2/HO-1, Wnt/beta-catenin, PERK/CHOP and SIRT1/FoxO3, targeted by agents like Curcumin and Mahuang Fuzi and Shenzhuo Decoction. The apoptosis, autophagy and pyroptosis section shows regulation via PERK/ATF4/CHOP and AMPK/SIRT1/PGC-1 axes, influenced by Salvia Miltiorrhiza and Polyphenolate. Mitophagy and pyroptosis are modulated by the PINK1/Parkin pathway, with Jianpi Qushi Heluo Formula affecting NLRP3 inflammasome. Apoptosis and pyroptosis involve Bcl-2/Bax and NLRP3/Caspase-1/GSDMD pathways, targeted by Compound Shelong Capsule. The central theme is TCM′s ability to simultaneously modulate multiple PCD processes, alleviating podocyte injury in MN.Diagram: TCM simultaneously modulates multiple PCD processes (apoptosis, autophagy, mitophagy, pyroptosis).Abbreviations: PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; β-catenin, beta-catenin; Wnt, wingless-type MMTV integration site family; STAT, signal transducer and activator of transcription; IL-6, interleukin-6; GRP78, glucose-regulated protein 78; PERK, protein kinase RNA-like endoplasmic reticulum kinase; CHOP, C/EBP homologous protein; miR-514a-5p, microRNA-514a-5p; TNFSF15, tumor necrosis factor superfamily member 15; BNIP3, BCL2 interacting protein 3; Notch1, neurogenic locus notch homolog protein 1; SIRT1, silent information regulator 1; FoxO3, forkhead box O3; HIF-1α, hypoxia-inducible factor 1α; Hes1, hairy and enhancer of split 1; NOX4, NADPH oxidase 4; AMPK, adenosine monophosphate-activated protein kinase; PINK1, PTEN-induced kinase 1; Parkin, parkin RBR E3 ubiquitin protein ligase; MMP, mitochondrial membrane potential; mtROS, mitochondrial reactive oxygen species; NLRP3, NOD-like receptor thermal protein domain-associated protein 3; Caspase-1, cysteinyl aspartate specific proteinase 1; IL-1β, interleukin-1β; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1α; ATF4, activating transcription factor 4; N-GSDMD, Gasdermin D N-terminal domain; GSDMD, Gasdermin D; Pro-IL-1β, pro-interleukin-1β; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; PCD, programmed cell death; MN, membranous nephropathy; TCMs, traditional Chinese medicines. TCM simultaneously modulates multiple PCD processes. The diagram illustrates how various TCM formulas, extracts, and active ingredients simultaneously modulate the key PCD modalities (apoptosis, autophagy, mitophagy, and pyroptosis) via core signaling cascades in podocytes during MN pathogenesis. Representative agents are shown, including: (1) Curcumin, Mahuang Fuzi and Shenzhuo Decoction, Modified Shengjiang Tongluo Soft Capsule, Jiangzhi Tongluo Soft Capsule, and Yishen Tongluo Formula, which target apoptosis and autophagy through pathways such as PI3K/Akt/mTOR, Nrf2/HO-1, Wnt/β-catenin, PERK/CHOP, and SIRT1/FoxO3; (2) Salvia miltiorrhiza Polyphenolate, which regulates apoptosis, autophagy, and pyroptosis by modulating the PERK/ATF4/CHOP and AMPK/SIRT1/PGC-1α axes; (3) Jianpi Qushi Heluo Formula, which ameliorates mitophagy dysfunction and subsequent NLRP3 inflammasome‑driven pyroptosis via the PINK1/Parkin pathway; and (4) Compound Shelong Capsule, which inhibits apoptosis and pyroptosis by targeting the Bcl-2/Bax and NLRP3/Caspase-1/GSDMD signaling axes. Collectively, these multi‑target effects of TCM highlight its unique advantage in simultaneously modulating multiple PCD processes and alleviating podocyte injury in MN. Solid arrow = activation, T-bar arrow = inhibition. A large number of TCMs can simultaneously modulate apoptosis and autophagy to maintain podocyte homeostasis. For instance, curcumin, a polyphenolic compound extracted from the rhizome of Curcuma longa, serves as the predominant bioactive ingredient of turmeric and exerts multiple biological effects, including anti-inflammatory and anti-tumor activities. It targets the PI3K/Akt/mTOR and Nrf2/HO‑1 pathways to coordinately regulate autophagy and apoptosis: it inhibits PI3K/mTOR signaling, activates Nrf2/HO‑1, enhances autophagy, suppresses apoptosis, and elevates antioxidant capacity to relieve oxidative injury.107 Similarly, Mahuang Fuzi and Shenzhuo Decoction (MFSD) modulates IL‑6/STAT3 inflammatory pathway and Wnt/β‑catenin signaling to inhibit apoptosis and upregulate autophagy, which is associated with reduced proteinuria and alleviated renal pathological lesions.108,109 Modified Shengjiang San exerts dual regulation of apoptosis and autophagy: it suppresses excessive apoptosis via inhibiting Notch and Hypoxia-inducible factor 1-alpha(HIF‑1α)/NOX4 pathways, while blocking abnormal PI3K/Akt/mTOR activation to relieve autophagy suppression.110–112 Jiangzhi Tongluo Soft Capsule, an extract derived from the TCM Curcuma longa, coordinately enhances autophagy via AMPK/mTOR signaling and inhibits intrinsic apoptosis through the SIRT1/FoxO3 axis.113,114 Yishen Tongluo Formula simultaneously suppresses apoptosis and promotes mitophagy via the GRP78/PERK/ATF4/CHOP pathway, the miR‑514a‑5p/Tumor necrosis factor superfamily member 15(TNFSF15) epigenetic axis, and BNIP3‑mediated mitophagy.115–117, Beyond concurrently regulating the above two PCD processes, numerous TCM also target additional cell death modalities and simultaneously modulate multiple PCD pathways to exert therapeutic effects in experimental MN models. Compound Shelong Capsule consists of four herbs. It intervenes in apoptosis and pyroptosis to dampen inflammatory cascades and tissue damage.118,119, Jianpi Qushi Heluo Formula enhances PINK1/Parkin‑mediated mitophagy, reduces mitochondrial ROS accumulation and MMP loss, and prevents NLRP3 inflammasome activation, thereby coordinating mitophagy and pyroptosis.120,121, Salvia miltiorrhiza Polyphenolate is an extract of the water-soluble components of Salvia miltiorrhiza, mainly containing polyphenols such as danshensu and salvianolic acid B, thereby possessing a broad spectrum of biological activities. In the context of MN, it concurrently modulates apoptosis, autophagy, and pyroptosis in parallel: it inhibits ERS‑ and mitochondria‑dependent apoptosis via the PERK/ATF4/CHOP pathway, activates protective autophagy through AMPK/Sirt1/peroxisome proliferator‑activated receptor gamma coactivator 1‑alpha (PGC‑1α) signaling, and suppresses pyroptotic effector proteins and pro‑inflammatory cytokine release.122–124 All in all, TCM formulations and their bioactive components holistically orchestrate multiple PCD processes in MN via multi‑target, multi‑pathway regulation. Regulation of TCM on Non-PCD Mechanisms in MN The pathogenesis of MN involves not only PCD but also multiple non‑PCD processes that indirectly orchestrate PCD‑driven injury. TCM blocks upstream pathological cascades and protects renal tissue by regulating inflammation, oxidative stress, immune disturbance, renal remodeling, and microbial dysbiosis. In terms of inflammation and immune regulation, Sanqi oral solution,126 Modified Huangqi Chifeng decoction,127 Astragaloside IV,128 Sodium houttuyfonate,129 Imperatae rhizoma-Hedyotis diffusa Willd. herbal pair,130 cinnamaldehyde,131 Shenkangling,132 Fangji Huangqi Decoction,133 Shengyang Yiwei Decoction,134 Colquhounia root tablet,135 skimmin and 7-hydoxycoumarin136 alleviate renal inflammatory infiltration and immune complex deposition by modulating NF‑κB, MAPK, JAK/STAT, and related pathways, thereby restoring immune homeostasis. As for oxidative stress and antioxidation, curcumin,137 Salvianolic acid A,138 Perilla Alcohol,139 and Dulcitol140 activate the Nrf2/HO‑1 and peroxisome proliferator‑activated receptor alpha (PPARα)/ATP‑binding cassette transporter A1 (ABCA1) pathways, scavenge ROS, and enhance antioxidant capacity. In renal fibrosis and tissue remodeling, SM934,141 Calycosin,142 Methylnissolin-3-O-Glucoside,143 and total flavonoids from Smilax glabra144 attenuate interstitial fibrosis and stabilize podocyte phenotype by inhibiting the TGF‑β/Smad and Wnt/β‑catenin pathways and epithelial‑mesenchymal transition (EMT). Regarding metabolic and microenvironmental regulation, monomers such as total flavonoids in Astragali Radix, salvianolic acid A, and paeoniflorin, as well as extracts and complexes regulate the renin‑angiotensin system, energy metabolism, calcium signaling, and endothelial homeostasis. They also target Soluble urokinase plasminogen activator receptor/Urokinase plasminogen activator receptor(suPAR/uPAR) and Peroxisome proliferator-activated receptor gamma/Angiopoietin-like 4(PPARγ/ANGPTL4) pathways, improve mitochondrial function, and modulate gut microbiota to exert multi‑dimensional renoprotection.145–154 Notably, these mechanisms constitute a sophisticated upstream cascade network that orchestrates PCD. Inflammation promotes PCD: TNF and Janus kinase(JAK)/STAT3 signaling activate apoptosis and pyroptosis.155,156 Oxidative stress serves as a shared upstream trigger for apoptosis and ferroptosis, and facilitates inflammasome assembly.157–159 Renal fibrosis represents the end‑stage outcome of sustained podocyte death and filtration barrier failure.160,161 Clinical Efficacy and Evidence of TCM Intervention in MN Building on the well‑established podocyte‑protective and PCD‑modulating effects of TCM, numerous TCM preparations have been widely adopted in clinical practice. These interventions consistently reduce proteinuria, elevate serum albumin levels, preserve renal function, and minimize adverse events. They can be administered either alone or in combination with glucocorticoids and immunosuppressants, offering a valuable therapeutic alternative for patients with refractory, recurrent, or treatment‑intolerant MN (Table 2). Table 2Clinical Trial of TCMs in MN TreatmentTCMsIntervention GroupControl GroupStudy DesignParticipantsNOutcomesRef.Shenqi particleShenqi particle 9.6g Tid for 48 weeks+Baiao Lumbrokinase capsule or Huoxue Tongmai capsule/Prospective, cohort clinical studyPMN112Primary outcome: CR, PR, NRSecondary outcomes: aPLA2R, eGFR[162]Shenqi particleShenqi particle 9.6 g Tid for 48 weeksPrednisone and cyclophosphamideRCTIMN190Primary outcome: CR, PRSecondary outcomes: ALB, eGFR, Scr, end-stage renal disease and death[163]Mahuang Fuzi and Shenzhuo DecoctionMahuang Fuzi and Shenzhuo Decoction 250mL bid for 6–36 months/Prospective, multicenter, open-label clinical trialPMN198Primary outcome: CR, PRSecondary outcomes: 24h UP, ALB, eGFR, aPLA2R[164]Mahuang Fuzi and Shenzhuo DecoctionMahuang Fuzi and Shenzhuo Decoction 200 mL bid for 6–36 months/Multicenter, nonrandomized, single-arm, clinical trialIMN184CR, PR, NR[164,165]Moshen granuleMoshen granule 40 g/d for 12 monthsPlaceboUnsureIMN47Urine volume, eGFR, 24h UP, UACR, ALB, Scr, urea, UA, ALT, AST, TG, TC, potassium, aPLA2R[145]Shuli Fenxiao formulaShulifenxiao formula 200mL bid at least 12 months/Retrospective studyRefractory IMN31Primary outcome: CR, PRSecondary outcomes: Scr, eGFR[166]Shuli Fenxiao formulaShuli Fenxiao formula 250mL bid for 24 weeks+CTX 50mg/Prospective case series studyPMN31Primary outcome: CR, PRSecondary outcomes: 24hUTP, Scr, ALB, TG, TC, LDL-C, PLA2R[167]Jian Pi Qu Shi FormulaJian Pi Qu Shi Formula/Retrospective Case-Series StudyIMN15Primary outcome: CR, PRSecondary outcomes: Urinary protein excretion, ALB, eGFR, ESRD and death[168]Jian Pi Qu Shi FormulaJian Pi Qu Shi Formula for 6 monthsImmunosuppressantsRCTIMN3024-hUP, ALB, Scr, Urea nitrogen, eGFR, complete blood counts, liver enzymes, intestinal flora[169]Tripterygium wilfordii polyglycoside tabletsTripterygium wilfordii polyglycoside tablets 40mg tid+tacrolimus or cyclosporine A for 12 monthsTacrolimus or cyclosporine+glucocorticoidsRetrospective analysisIMN64Primary outcome: CR, PR, NRSecondary outcomes: Scr, ALB, TG, LDL-C, aPLA2R, AST, ALT[170]Colquhounia root tabletColquhounia root tablet 3–5 tablets tid+ACEI/ARB for 12 monthsACEI/ARBRetrospective analysisIMN44Primary outcome: CR, PRSecondary outcomes: 24h UP, ALB, eGFR[171]Abbreviations: RCT, Randomized Controlled Trial; IMN, Idiopathic Membranous Nephropathy; CR, Complete remission; PR, Partial remission; ALB, Albumin; eGFR, Estimated Glomerular Filtration Rate; SCr, serum creatinine; PMN, primary membranous nephropathy; NR, Non-remission; aPLA2R, Anti-Phospholipase A2 Receptor Antibody; 24h UP,24-h urinary protein; UACR, Urine Albumin-to-Creatinine Ratio; UA, Uric Acid; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; TG, Triglyceride; TC, Total Cholesterol; CTX, Cyclophosphamide; LDL-C, Low-density lipoprotein-cholesterol;ACEI, Angiotensin-Converting Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker. Table 2Clinical Trial of TCMs in MN TreatmentTCMsIntervention GroupControl GroupStudy DesignParticipantsNOutcomesRef.Shenqi particleShenqi particle 9.6g Tid for 48 weeks+Baiao Lumbrokinase capsule or Huoxue Tongmai capsule/Prospective, cohort clinical studyPMN112Primary outcome: CR, PR, NRSecondary outcomes: aPLA2R, eGFR[162]Shenqi particleShenqi particle 9.6 g Tid for 48 weeksPrednisone and cyclophosphamideRCTIMN190Primary outcome: CR, PRSecondary outcomes: ALB, eGFR, Scr, end-stage renal disease and death[163]Mahuang Fuzi and Shenzhuo DecoctionMahuang Fuzi and Shenzhuo Decoction 250mL bid for 6–36 months/Prospective, multicenter, open-label clinical trialPMN198Primary outcome: CR, PRSecondary outcomes: 24h UP, ALB, eGFR, aPLA2R[164]Mahuang Fuzi and Shenzhuo DecoctionMahuang Fuzi and Shenzhuo Decoction 200 mL bid for 6–36 months/Multicenter, nonrandomized, single-arm, clinical trialIMN184CR, PR, NR[164,165]Moshen granuleMoshen granule 40 g/d for 12 monthsPlaceboUnsureIMN47Urine volume, eGFR, 24h UP, UACR, ALB, Scr, urea, UA, ALT, AST, TG, TC, potassium, aPLA2R[145]Shuli Fenxiao formulaShulifenxiao formula 200mL bid at least 12 months/Retrospective studyRefractory IMN31Primary outcome: CR, PRSecondary outcomes: Scr, eGFR[166]Shuli Fenxiao formulaShuli Fenxiao formula 250mL bid for 24 weeks+CTX 50mg/Prospective case series studyPMN31Primary outcome: CR, PRSecondary outcomes: 24hUTP, Scr, ALB, TG, TC, LDL-C, PLA2R[167]Jian Pi Qu Shi FormulaJian Pi Qu Shi Formula/Retrospective Case-Series StudyIMN15Primary outcome: CR, PRSecondary outcomes: Urinary protein excretion, ALB, eGFR, ESRD and death[168]Jian Pi Qu Shi FormulaJian Pi Qu Shi Formula for 6 monthsImmunosuppressantsRCTIMN3024-hUP, ALB, Scr, Urea nitrogen, eGFR, complete blood counts, liver enzymes, intestinal flora[169]Tripterygium wilfordii polyglycoside tabletsTripterygium wilfordii polyglycoside tablets 40mg tid+tacrolimus or cyclosporine A for 12 monthsTacrolimus or cyclosporine+glucocorticoidsRetrospective analysisIMN64Primary outcome: CR, PR, NRSecondary outcomes: Scr, ALB, TG, LDL-C, aPLA2R, AST, ALT[170]Colquhounia root tabletColquhounia root tablet 3–5 tablets tid+ACEI/ARB for 12 monthsACEI/ARBRetrospective analysisIMN44Primary outcome: CR, PRSecondary outcomes: 24h UP, ALB, eGFR[171]Abbreviations: RCT, Randomized Controlled Trial; IMN, Idiopathic Membranous Nephropathy; CR, Complete remission; PR, Partial remission; ALB, Albumin; eGFR, Estimated Glomerular Filtration Rate; SCr, serum creatinine; PMN, primary membranous nephropathy; NR, Non-remission; aPLA2R, Anti-Phospholipase A2 Receptor Antibody; 24h UP,24-h urinary protein; UACR, Urine Albumin-to-Creatinine Ratio; UA, Uric Acid; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; TG, Triglyceride; TC, Total Cholesterol; CTX, Cyclophosphamide; LDL-C, Low-density lipoprotein-cholesterol;ACEI, Angiotensin-Converting Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker. Clinical Trial of TCMs in MN Treatment Abbreviations: RCT, Randomized Controlled Trial; IMN, Idiopathic Membranous Nephropathy; CR, Complete remission; PR, Partial remission; ALB, Albumin; eGFR, Estimated Glomerular Filtration Rate; SCr, serum creatinine; PMN, primary membranous nephropathy; NR, Non-remission; aPLA2R, Anti-Phospholipase A2 Receptor Antibody; 24h UP,24-h urinary protein; UACR, Urine Albumin-to-Creatinine Ratio; UA, Uric Acid; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; TG, Triglyceride; TC, Total Cholesterol; CTX, Cyclophosphamide; LDL-C, Low-density lipoprotein-cholesterol;ACEI, Angiotensin-Converting Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker. Clinical Efficacy of TCM Compound Formulations Classic TCM formulas demonstrate reliable efficacy in IMN and refractory cases, with distinct advantages for personalized therapy. Among these, Shenqi Particle and Mahuang Fuzi and Shenzhuo Decoction (MFSD) have been experimentally validated to regulate PCD in MN, and clinical trials have further confirmed their remarkable efficacy and favorable safety profiles. One randomized controlled trial (RCT) and one prospective cohort study have shown that multicomponent hospital preparation Shenqi Particle monotherapy provides a remission rate comparable to glucocorticoid plus cyclophosphamide therapy in IMN patients, with superior renal protection and fewer adverse reactions. Notably, it exhibits superior efficacy in anti‑PLA2R‑negative patients and holds potential as a replacement for standard immunosuppressive regimens.162,172 MFSD represents a canonical TCM formula for MN management. One prospective, multicenter, open-label clinical trial and one multicenter, non-randomized, single-arm clinical trial have confirmed its high long‑term remission rate, which is unaffected by age or prior immunosuppressive treatment, supporting its broad clinical applicability.163,164 Moshen Granule (MSG) significantly improves clinical parameters and reduces anti‑PLA2R antibody titers.145 For refractory and high-risk patients, one retrospective case series and one prospective case series have demonstrated that Shuli Fenxiao Formula administered alone or combined with low‑dose immunosuppressants significantly elevates remission rates.165,166 Jian Pi Qu Shi Formula (JPQSF) exerts therapeutic effects by invigorating the spleen, eliminating dampness, and balancing yin and yang. One RCT and one retrospective case series have demonstrated that JPQSF achieves an 80% complete remission rate after one-year treatment in patients with refractory IMN and ameliorates intestinal flora dysbiosis.167,168 Clinical Efficacy of Herbal Extracts Herbal extracts are widely used clinically due to their well‑defined pharmacological activities and convenient administration. Tripterygium wilfordii polyglycoside tablets (TWPs), a standardized total glycoside mixture extracted from the medicinal herb Tripterygium wilfordii Hook. f., exert potent anti‑inflammatory, immunosuppressive, and podocyte‑protective effects. Retrospective studies have demonstrated that when combined with tacrolimus or cyclosporine, TWPs can more rapidly reduce proteinuria and improve overall response rates.169 Colquhounia root tablet (CRT), a herbal extract derived from Colquhounia root, exhibits potent immunosuppressive activity. A retrospective study has shown that when combined with angiotensin-converting enzyme inhibitor(ACEI)/angiotensin II receptor blocker(ARB) regimens, it markedly increases remission rates with mild adverse events and no severe myelosuppression, making it suitable for long‑term use in patients with mild‑to‑moderate MN.170 Wuzhi soft capsule (WZC), an herbal extract derived from Schisandra sphenanthera (Southern Wuweizi), significantly elevates tacrolimus blood concentrations to achieve synergistic efficacy, providing an effective strategy for enhancing therapeutic effects while reducing toxicity in refractory cases.171 Systematic Review and Meta-Analysis Evidence Multiple meta‑analyses have provided high‑level evidence supporting TCM for MN. Consistently, formulations containing Astragalus, Tripterygium wilfordii, and Wuzhi, when combined with conventional therapy, significantly increase remission rates, improve clinical indices, and reduce adverse events.173,174 Chinese herbal injections are widely used for their rapid onset. Danhong Injection and Dengzhanhua Injection combined with conventional therapy have been proposed as promising optimal regimens for nephrotic syndrome.175 Further analyses focusing on Tripterygium wilfordii Hook F (TwHF) and its extracts confirm that both monotherapy and combination with glucocorticoids significantly enhance efficacy with manageable toxicity.176–178 Collectively, available evidence strongly supports the clinical utility of TCM in MN. Nevertheless, limitations including low methodological quality and relatively short follow‑up durations persist, warranting further optimization and rigorous validation in future investigations. Discussion This review comprehensively demonstrates that both complement‑dependent and complement‑independent signaling pathways orchestrate multiple PCD in MN via multiple intracellular signaling cascades, thereby exacerbating podocyte damage and progressive renal parenchymal injury. TCM formulas, herbal extracts, and active monomers exert therapeutic effects by targeting a spectrum of signaling pathways and converging on the central regulatory node of PCD, thereby establishing a mechanistic basis for novel therapeutic development in MN. Despite substantial progress, current research remains hindered by numerous limitations and bottlenecks, which restrict the standardized clinical application, translational implementation, and international recognition of TCM for MN. Firstly, the chemical composition of TCM formulas is highly complex, and the key bioactive components responsible for therapeutic efficacy remain largely undefined, leading to insufficient mechanistic depth. Although the core advantage of TCM lies in its multi‑component, multi‑target regulatory paradigm, such complexity also presents formidable challenges for mechanistic dissection. Most existing studies on TCM formulas are limited to descriptive efficacy observations and single‑pathway analyses. The identification of core active constituents and their synergistic interactions remains inadequate, impeding the refinement, optimization, and modernization of TCM. Secondly, emerging research areas including novel signaling axes, non‑coding RNAs, and epigenetic regulation remain underinvestigated, restricting comprehensive mechanistic exploration. Thirdly, most available studies focus on the simultaneous regulatory effects of TCM on two or more PCD subtypes in MN, whereas direct molecular crosstalk among different PCD pathways remains insufficiently clarified. Furthermore, it remains uncertain whether the interactions between PCD pathways consistently produce synergistic therapeutic benefits. In addition, current research on PCD regulatory mechanisms in MN is markedly unbalanced. Existing literature predominantly focuses on four classical PCD subtypes: apoptosis, pyroptosis, ferroptosis, and autophagy. In contrast, other emerging PCD modalities, including necroptosis, cuproptosis, disulfidptosis, PANoptosis, and oxeitosis, have rarely been investigated in the pathogenesis of MN. At present, systematic studies are lacking regarding whether these newly identified PCD forms participate in podocyte injury, whether they crosstalk with well-characterized PCD pathways, and whether TCM interventions exert regulatory effects on these processes. Fourthly, most current mechanistic evidence is derived from preclinical studies, including rodent PHN/C-BSA models and immortalized podocyte cell lines. These experimental models differ from human MN in terms of immune subtypes and complement activation patterns, and immortalized podocyte lines fail to fully recapitulate the in vivo microenvironment. Filling this research gap will help comprehensively unravel the complex pathological network of MN, and provide novel theoretical basis and promising research directions for the multi‑target intervention strategy of TCM. Moving forward, further efforts are warranted to identify core bioactive components of TCM formulas and characterize their precise molecular targets. Integrating metabolomics, high‑throughput screening, nanoengineering, and component‑based Chinese medicine (CCM) will enable systematic isolation, identification, and optimization of bioactive constituents, bridging TCM with modern science and enhancing therapeutic consistency.179 Concurrently, greater emphasis should be placed on the central regulatory nodes governing PCD network crosstalk to fully leverage the multi‑herb, multi‑component, multi‑target nature of TCM and delineate its regulatory effects on intermodal PCD crosstalk, thereby improving pathological outcomes and prognosis in MN. In addition, it is essential to actively excavate and clarify the potential regulatory mechanisms of other understudied PCD subtypes in MN pathogenesis. Furthermore, intensified investigation into emerging fields—including multi‑omics and organoid‑driven identification of PCD‑related biomarkers—will facilitate precise target mapping and support evidence‑based TCM screening and rational drug design. Notably, the pharmacokinetic/pharmacodynamic (PK/PD) profiles of TCM active constituents—key determinants governing their in vivo therapeutic efficacy against MN—remain insufficiently characterized, and this challenge is further compounded by the inherent physicochemical drawbacks of numerous bioactive ingredients. This knowledge gap restricts our understanding of in vivo therapeutic efficacy and highlights the urgent necessity of prioritizing PK/PD evaluation in future mechanistic research. Unlike conventional chemical drugs with well-defined absorption, distribution, metabolism and excretion (ADME) properties and predictable in vivo behaviors, TCM preparations are inherently multi-component systems. Each constituent exhibits distinct PK characteristics, including oral bioavailability, plasma protein binding rate, tissue distribution patterns, metabolic pathways and elimination half-life. These complex PK properties directly determine the exposure level and duration of active ingredients at podocyte injury sites, thereby shaping subsequent PD responses, particularly the regulatory effects on PCD signaling cascades. For instance, multiple bioactive monomers summarized in this review (such as curcumin, baicalin, and tetrandrine) exert definite anti-apoptotic or anti-pyroptotic activities in vitro. However, their poor water solubility, prominent first-pass metabolism, and low renal bioavailability severely constrain their in vivo therapeutic performance. The actual concentration of these agents reaching glomerular podocytes may fall below the threshold required for sustained modulation of pivotal pathways such as PI3K/Akt/mTOR and Nrf2/HO-1. Such disconnection between potent in vitro PD activity and suboptimal in vivo PK properties partially accounts for the unsatisfactory clinical translation of TCM interventions for MN. From a translational perspective, such discrepancies warn that the therapeutic potential of TCM-derived compounds should be interpreted with caution. Moreover, PK/PD profiling should be regarded as a prerequisite prior to animal modeling and clinical validation. Furthermore, the PK/PD relationship of TCM compound formulas becomes even more intricate due to herb–herb interactions. Formula compatibility can alter the PK behaviors of individual components by enhancing intestinal absorption, inhibiting metabolic enzymes, or competitively displacing plasma protein binding, thereby triggering synergistic or antagonistic PK/PD effects. Consequently, only a minimal fraction of bioactive constituents can reach renal target lesions, which not only weakens therapeutic outcomes but also elevates the risk of systemic adverse reactions. To address the above limitations, future research should adopt an integrated two-pronged strategy. On one hand, systematic PK/PD profiling should be prioritized for lead TCM compounds and compound prescriptions. Strategies such as LC-MS/MS-based multi-component PK analysis, physiologically based pharmacokinetic (PBPK) modeling, and PK/PD correlation modeling that links concentration–time curves with dynamic alterations in PCD-related biomarkers (eg, caspase-3 activity, GPX4 expression, and LC3-II/I ratio) should be extensively applied. Such efforts will clarify the effective therapeutic window, optimal dosing frequency and target occupancy, providing fundamental theoretical evidence for rational compatibility and clinical regimen design of TCM. On the other hand, nanomedicine-based renal-targeted delivery systems, including nanoplatforms, liposomes and hydrogels, should be developed to enhance renal accumulation, improve bioavailability, prolong half-life and reduce systemic side effects.180,181 These complementary strategies are expected to bridge the gap between in vitro potency and in vivo therapeutic efficacy of TCM-derived bioactive ingredients against MN. In addition, with respect to TCM safety, several TCM preparations exert therapeutic effects against MN while exhibiting inherent toxic risks. For instance, although accumulating clinical studies and meta-analyses have validated the favorable efficacy of Tripterygium wilfordii, its well-recognized gonadal, hepatic, and hematologic toxicities remain a major concern. Accordingly, prudent patient selection, regular monitoring of liver function and blood routine parameters, and comprehensive risk–benefit assessment are indispensable during clinical administration. Currently, systematic toxicological investigations are lacking, and standardized monitoring frameworks are absent. Few studies included in this review have conducted rigorous toxicological or safety assessments. Future research must strengthen systematic toxicological evaluation, clarify toxic components and their mechanisms, establish standardized assessment systems and long‑term monitoring protocols, characterize dose–toxicity relationships, identify potentially hazardous constituents, and define safe dosage ranges. Concurrently, TCM compatibility and processing methodologies should be optimized to attenuate toxicity through rational formulation and standardized preparation. In clinical research, most studies are retrospective. Available RCTs are limited by small sample sizes, short follow‑up durations, and substantial risk of bias, impeding robust validation of efficacy and safety. For chronic progressive diseases such as MN, small sample sizes and short observation periods are insufficient to evaluate long‑term outcomes including progression to end‑stage renal disease. Furthermore, current evaluation systems rely predominantly on conventional clinical indices including proteinuria, serum creatinine, and albumin, lacking correlation with PCD‑related biomarkers and thus limiting accurate mechanistic and therapeutic quantification. To address these gaps, future investigations should implement large‑scale, multi‑center, long‑term follow‑up RCTs with rigorous randomization, blinding, and placebo control to minimize bias and enhance reproducibility. Efficacy evaluation should be upgraded by incorporating PCD‑related biomarkers, such as dynamic monitoring of specific proteins, metabolites, and microRNAs in blood, urine, or feces before and after TCM intervention. This strategy will not only identify novel therapeutic targets but also establish mechanism‑based efficacy evaluation directly linked to PCD regulation. Furthermore, potential publication bias should be acknowledged for the preclinical studies incorporated in this review. Some primary studies present selective reporting, in which negative findings including statistically non-significant outcomes and adverse endpoints are frequently left unpublished. Such reporting bias may overstate the multi-target renoprotective potency of TCM, which in turn constrains the external validity of efficacy conclusions and hinders their translation into clinical practice to a certain extent. Future studies are required to rigorously validate the mechanistic pathways and multi-target regulatory effects of TCM, alongside full data disclosure to alleviate publication bias. Finally, advances in artificial intelligence (AI) provide unprecedented opportunities to decode the multi‑component, multi‑target complexity of TCM in MN pathogenesis. Network pharmacology and molecular docking serve as foundational frameworks to construct herb–compound–disease–target–PCD interaction networks. Machine learning enables high‑throughput virtual screening, integrated PK/PD profiling (ADME and target occupancy kinetics), and filtration of potentially toxic or interactive components. Relying on the cutting-edge AI protein structure prediction model AlphaFold, together with unsupervised clustering and the Walktrap algorithm, researchers can accurately resolve the three-dimensional spatial conformations of core PCD target proteins including GPX4 and NLRP3, identify the binding pockets and binding affinity between active small molecules of TCM and their targets, calculate the proportion combinations of different herb pairs and multi-herb medicinal materials through algorithm iteration, intelligently optimize the compatibility ratio of TCM compound prescriptions, screen the optimal compatibility schemes with synergistic effects, and promote the efficient mining of active compounds in TCM.182 Deep learning further models the PCD network as a dynamic system to simulate TCM‑mediated modulation of crosstalk. Clinically, AI facilitates biomarker‑driven precision therapy by integrating clinical, pathological, and PCD‑related data. Moreover, AI can be applied to optimize nanomedicine design—predicting nanoparticle size, surface modification, and drug release profiles to maximize kidney-targeted delivery efficiency and minimize off-target effects. It also enables fingerprint‑based quality control correlated with biological activity. Additionally, natural language processing can mine real‑world evidence from electronic medical records regarding TCM efficacy and safety in MN. Nevertheless, the practical application of these technologies in MN research remains very limited. Conclusion This review systematically summarizes the pathogenic contribution of PCD to MN. Multiple PCD subtypes synergistically trigger podocyte loss and glomerular barrier damage via interconnected signaling cascades, acting as central drivers of MN progression. As a multi-component and multi-target therapeutic regimen, TCM can modulate multiple signaling pathways to regulate PCD and alleviate podocyte injury, alongside concurrent improvement of secondary pathological disturbances such as inflammation, oxidative stress and renal fibrosis. Clinical observations suggest adjuvant TCM use may raise disease remission rates and lower adverse reaction risks for difficult-to-treat MN. While these outcomes reveal preliminary therapeutic potential, the overall evidence foundation remains suboptimal, constrained by incomplete identification of key pharmacodynamic substances, unfavorable pharmacokinetic profiles of active ingredients, inadequate renal-targeted delivery efficiency, insufficient safety and toxicological evaluation, as well as inherent publication bias among enrolled studies. To facilitate rigorous translational progress, three tiered priority research directions are proposed as actionable next steps. Primary emphasis should be placed on integrated PK/PD profiling to quantify the renal exposure and effective concentration of TCM bioactive ingredients. Second, smart drug delivery systems ought to be developed to resolve core bottlenecks including low bioavailability, prominent first-pass metabolism and inadequate renal accumulation, so as to amplify therapeutic efficacy and reduce systemic toxicity simultaneously. Finally, well-designed multicenter RCTs incorporating PCD molecular biomarkers are required to validate clinical efficacy objectively. Beyond these experimental and clinical validations, artificial intelligence (AI) -driven drug screening and structural optimization can further accelerate the development of high-efficiency, low-toxicity renal-targeted agents targeting PCD pathways. Though TCM-mediated PCD modulation represents a promising low-toxic therapeutic direction for MN, comprehensive systematic verification across preclinical and clinical tiers is indispensable before formal clinical popularization.